LCTX

#2786
Lineage Cell Therapeutics, Inc. Common Stock
1.3 4 USD
+9900.00%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
1.34
1.35
Range Annuel
0.01
1.98
Changement quotidien
+9900.00%
Changement Mensuel
-10.65%
Evolution sur 6 mois
-21.96%
Changement Annuel
-21.96%
Clôture Précédente
0.0 1
Open
1.3 5
Low
1.3 4
High
1.3 5
Volume
19
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur 202020212022202320242025 TTM

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

Nouvelles